IMMU - Immunomedics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
6/29/2018
6/29/2017
6/29/2016
Total Revenue
1,466
2,156
3,091
3,233
Cost of Revenue
120,723
143,203
82,241
62,241
Gross Profit
-119,257
-141,047
-79,150
-59,008
Operating Expenses
Research Development
120,180
99,283
51,776
53,492
Selling General and Administrative
57,361
43,307
29,982
7,590
Total Operating Expenses
57,361
43,307
29,982
7,590
Operating Income or Loss
-176,618
-141,047
-79,150
-59,008
Interest Expense
30,750
23,255
5,480
5,480
Total Other Income/Expenses Net
-5,575
-101,916
-68,723
-40
Income Before Tax
-219,178
-273,731
-153,245
-64,190
Income Tax Expense
156
156
21
-5,054
Income from Continuing Operations
-219,334
-273,887
-153,266
-59,136
Net Income
-219,261
-273,837
-153,206
-59,037
Net Income available to common shareholders
-219,261
-273,837
-153,206
-59,037
Reported EPS
Basic
-
-1.78
-1.47
-0.62
Diluted
-
-1.78
-1.47
-0.62
Weighted average shares outstanding
Basic
-
153,475
104,536
94,770
Diluted
-
153,475
104,536
94,770
EBITDA
-
-250,476
-79,150
-59,008